Repligen Corporation logo

Repligen Corporation(RGEN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$170.29
11/19/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RGEN

11/19/2026: RGEN (2-star) is currently NOT-A-BUY. Pass it for now.

Repligen Corporation is a mid-cap life sciences tools company that specializes in bioprocessing consumables and systems for biological drug manufacturing. The company benefits from strong gross margins, proprietary filtration and chromatography technologies, and recurring revenue streams from consumable product lines. Its primary growth driver centers on capturing demand in advanced modalities like gene therapy, reinforced by strategic expansions such as the BioLife Solutions integration. However, the business faces risks related to customer inventory cycles, elevated valuation multiples, and the execution challenge of resolving internal financial control weaknesses. The stock best suits growth-oriented investors willing to navigate cyclical biopharma spending trends while monitoring order book recovery and integration milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveRepligen targets expansion in high-growth bioprocessing and cell therapy segments.
Momentum investorStrong fit while signal remains positiveThe stock experiences notable price momentum during periods of biopharmaceutical industry order recovery.
Value investorMixed fitValuation multiples often remain elevated relative to traditional industrial or healthcare peers due to long-term growth expectations.
Dividend investorWeak fitThe company does not pay dividends, prioritizing capital reinvestment and M&A.
Low-risk investorWeak fitEarnings volatility and cyclical industry exposure create notable equity price fluctuations.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock is sensitive to shifts in biopharmaceutical capital expenditure cycles and sector sentiment.
Valuation riskHighPricing often reflects optimistic long-term growth assumptions, leaving little room for execution missteps.
Competition risk (large conglomerate competition)Medium / highWell-capitalized life science giants can bundle competing bioprocessing products.
Business qualityStrongRepligen features high gross margins and strong technological positioning in core niche workflows.
Dividend incomeLow / noneIncome-focused investors receive no cash return via dividends.
Execution riskMedium / highIntegrating large acquisitions like BioLife Solutions while resolving internal financial control weaknesses demands careful management.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 11.04B USD
Price to earnings Ratio -
1Y Target Price 203.21
Price to earnings Ratio -
1Y Target Price 203.21
Volume (30-day avg) 1.2M shares
Beta 1.12
52 Weeks Range 100.99 - 198.87
Updated Date 11/19/2026
52 Weeks Range 100.99 - 198.87
Updated Date 11/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
40.0%
Active BUY / eligible
2 / 5
30-Day BUY Count Change
0

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 0.22%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/19/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RGEN receives a 4-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
RGEN has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+291.6%) and solid cash generation (FCF margin 12.7%) are partially offset by soft profitability (net margin 6.6%), modest insider ownership of 4.87%.

Financial Health Rating

★★★★★
RGEN's financial health is supported by solid cash strength, including free-cash-flow generation (12.7% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is RGEN's strongest growth driver at +291.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+16.4%, solid) is also solid, while free-cash-flow growth (-34.1%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 112.6% and approximately 95.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.87% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.42%
FMR Inc 5.20%
United Capital Financial Advisers Inc 4.37%
Vanguard Capital Management, LLC 3.77%
Vanguard Portfolio Management, LLC 3.62%

Unit Economics (Per $1K Revenue)

★★★★★
RGEN generates approximately $471 of gross profit, $81 of operating income, and $127 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and solid cash conversion support a 3-star rating, while capital efficiency is weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.62%

Quantitative Style Profile

★★★★★
RGEN has a large-cap, liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Large / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Filtration ProductsSingle-use and reusable hollow-fiber and flat-sheet filtration modules used in upstream and downstream processing.This is the company's largest revenue pillar, driven by recurring customer demand for consumable filtration items.
Chromatography ProductsOPUS pre-packed columns and systems designed to streamline biomolecule separation.Provides efficient purification solutions that save drug developers significant time in manufacturing setup.
Proteins ProductsAffinity ligands and specialized resins used for high-purity biological drug isolation.Offers high-margin, proprietary inputs integral to monoclonal antibody and gene therapy manufacturing.
Process AnalyticsReal-time sensing and desktop analytical instruments (PAT).Helps clients monitor production quality and optimize yields during active drug manufacturing batches.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-10-27
When Before Market
Estimate 0.46
Actual 0.53

Profitability

Profit Margin -1.47%
Operating Margin (TTM) 8.14%

Management Effectiveness

Return on Assets (TTM) 1.4%
Return on Equity (TTM) -0.57%

Valuation

Trailing PE -
Forward PE 58.48
Enterprise Value 10.19B
Price to Sales(TTM) 13.7
Enterprise Value 10.19B
Price to Sales(TTM) 13.7
Enterprise Value to Revenue 12.65
Enterprise Value to EBITDA 80
Shares Outstanding 63.92M
Shares Floating 60.96M
Shares Outstanding 63.92M
Shares Floating 60.96M
Percent Insiders 4.87
Percent Institutions 112.64

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.